Emerging therapies targeting the ubiquitin proteasome system in cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging therapies targeting the ubiquitin proteasome system in cancer
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 1, Pages 6-12
Publisher
American Society for Clinical Investigation
Online
2014-01-01
DOI
10.1172/jci71602
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Emerging Role of the Ubiquitin Proteasome in Pulmonary Biology and Disease
- (2013) Nathaniel M. Weathington et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Identification of repurposed small molecule drugs for chordoma therapy
- (2013) Menghang Xia et al. CANCER BIOLOGY & THERAPY
- Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
- (2013) R. Voltan et al. CLINICAL CANCER RESEARCH
- Pomalidomide: First Global Approval
- (2013) Shelley Elkinson et al. DRUGS
- Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin
- (2013) Ning Wu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting F Box Protein Fbxo3 To Control Cytokine-Driven Inflammation
- (2013) R. K. Mallampalli et al. JOURNAL OF IMMUNOLOGY
- A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulate inflammation
- (2013) Bill B Chen et al. NATURE IMMUNOLOGY
- Rapid Identification of Antifungal Compounds against Exserohilum rostratum Using High Throughput Drug Repurposing Screens
- (2013) Wei Sun et al. PLoS One
- Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus
- (2013) L. Quartuccio et al. RHEUMATOLOGY
- Linear ubiquitination: a newly discovered regulator of cell signalling
- (2013) Eva Rieser et al. TRENDS IN BIOCHEMICAL SCIENCES
- Skp-cullin-F box E3 ligase component FBXL2 ubiquitinates Aurora B to inhibit tumorigenesis
- (2013) B B Chen et al. Cell Death & Disease
- Refractory SLE patients respond to the proteasome inhibitor bortezomib
- (2012) F Hiepe et al. ANNALS OF THE RHEUMATIC DISEASES
- Ubiquitin and Membrane Protein Turnover: From Cradle to Grave
- (2012) Jason A. MacGurn et al. Annual Review of Biochemistry
- An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
- (2012) R. Vij et al. BLOOD
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance
- (2012) A. Broyl et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- Design and rationale of FOCUS (PX-171-011): A randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM)
- (2012) Roman Hájek et al. BMC CANCER
- An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
- (2012) Ravi Vij et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
- (2012) Dharminder Chauhan et al. CANCER CELL
- P53 Mdm2 Inhibitors
- (2012) Kareem Khoury et al. CURRENT PHARMACEUTICAL DESIGN
- Governance of Endocytic Trafficking and Signaling by Reversible Ubiquitylation
- (2012) Michael J. Clague et al. DEVELOPMENTAL CELL
- Targeting the von Hippel–Lindau E3 Ubiquitin Ligase Using Small Molecules To Disrupt the VHL/HIF-1α Interaction
- (2012) Dennis L. Buckley et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
- (2012) M A Hurchla et al. LEUKEMIA
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts
- (2011) Cyrus Chargari et al. CANCER LETTERS
- An Allosteric Inhibitor of the Human Cdc34 Ubiquitin-Conjugating Enzyme
- (2011) Derek F. Ceccarelli et al. CELL
- Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes
- (2011) Mikael Altun et al. CHEMISTRY & BIOLOGY
- A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors
- (2011) J. Tabernero et al. CLINICAL CANCER RESEARCH
- Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
- (2011) Michael Millward et al. INVESTIGATIONAL NEW DRUGS
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of proteasome deubiquitinating activity as a new cancer therapy
- (2011) Pádraig D'Arcy et al. NATURE MEDICINE
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest
- (2011) B B Chen et al. ONCOGENE
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
- (2011) R. Huang et al. Science Translational Medicine
- Human ITCH E3 Ubiquitin Ligase Deficiency Causes Syndromic Multisystem Autoimmune Disease
- (2010) Naomi J. Lohr et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Pharmacologic Inhibition of the Anaphase-Promoting Complex Induces A Spindle Checkpoint-Dependent Mitotic Arrest in the Absence of Spindle Damage
- (2010) Xing Zeng et al. CANCER CELL
- Deubiquitinase Inhibition by Small-Molecule WP1130 Triggers Aggresome Formation and Tumor Cell Apoptosis
- (2010) V. Kapuria et al. CANCER RESEARCH
- Sent to Destroy
- (2010) Monte S. Willis et al. CIRCULATION RESEARCH
- A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
- (2010) H. Wang et al. MOLECULAR CANCER THERAPEUTICS
- Enhancement of proteasome activity by a small-molecule inhibitor of USP14
- (2010) Byung-Hoon Lee et al. NATURE
- An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase
- (2010) Stephen Orlicky et al. NATURE BIOTECHNOLOGY
- Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase
- (2010) Mariam Aghajan et al. NATURE BIOTECHNOLOGY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes
- (2009) S-C Sun CELL DEATH AND DIFFERENTIATION
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- Breaking the chains: structure and function of the deubiquitinases
- (2009) David Komander et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Thalidomide for treatment of multiple myeloma: 10 years later
- (2008) A. Palumbo et al. BLOOD
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now